Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Change in Working Capital · Q4 FY2025 · quarter ended Dec 2025

Change in working capital declines year over year

Q4 FY2025 change in working capital of $52K (cash outflow) fell 76.8% year over year.

Context

  • Change in working capital increased in 1 of the last 2 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$52K-112.0% QoQ
Last fiscal yearDec 2025
$316K+150.9% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-76.8%——
1 year+150.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
316K USD
Year-over-year change
+150.9%
2-year CAGR
-7.5%

Change in Working Capital vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's FY2025 change in working capital of $316K is the 6th largest of the 8 companies compared; the peer median is $1.42M.
  • Its year-over-year change of +150.9% is the highest of 6, against a peer median of -84.9%.
PLYX Competitors Peer median
Change in Working Capital for PLYX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$31.04M -3.9%—110.0%
PTHSPelthos Therapeutics Inc.LTM Mar 2026$9.26M -928.5%—33.4%
JBIOJade Biosciences, Inc.LTM Mar 2026$1.97M ———
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$1.68M -27.0%-64.7%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.42M -84.9%-50.6%4593.5%
PLYXPolaryx Therapeutics, Inc. Common StockFY2025$316K +150.9%——
CBIOCrescent Biopharma, Inc.LTM Mar 2026$131.32K -106.7%+42.1%1.1%
KLRSKalaris Therapeutics IncLTM Mar 2026$53K —+0.3%—
Peer median (excluding PLYX) $1.42M-84.9%-25.1%71.7%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.